Cathy Hammerman

Cathy Hammerman

Auto-generated profile, based on publicly available information

Cathy Hammerman

Department of Neonatology, Shaare Zedek Medical Center, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Pediatrics
Verified
Journal Article
Closed access
PDF file
CHCathy Hammerman
Cathy Hammerman
ABAlona Bin-Nun
Alona Bin-Nun
EMEinat Markovitch
Einat Markovitch
MSMichael S. Schimmel
Michael S. Schimmel
MKMichael Kaplan
Michael Kaplan
DFDaniel Fink
Daniel Fink
Standard pharmacologic closure of the patent ductus arteriosus currently involves the administration of 1 of 2 cyclooxygenase inhibitors: either indomethacin or ibuprofen. However, both of these drugs can be associated with potentially significant adverse effects. We present here the cases of 5 preterm infants (gestational age: 26–32 weeks; postnatal age: 3–35 days) with large, hemodynamically significant patent ductus arteriosus who had either failed or had contraindications to ibuprofen therapy. Each of these infants was treated with off-label oral paracetamol (15 mg/kg per dose every 6 hours). Ductal closure was achieved within 48 hours in all the treated infants. No toxicity was observed.

9 November 2006 in BMJ
Verified
Journal Article
Closed access
PDF file
CHCathy Hammerman
Cathy Hammerman
ABAlona Bin-Nun
Alona Bin-Nun
MKMichael Kaplan
Michael Kaplan
Background The human intestine is home to more than a trillion live bacteria from about 400 species. The average adult body contains about 20 times more bacteria than it does cells.1 In the natural environment a delicate symbiosis evolves between these endogenous bacteria and their host. The vital contribution of natural flora to normal intestinal development is underscored by studies of animals raised in a germ-free environment. These animals have hypoplastic intestinal epithelia, reduced gut immunity, and impaired peristalsis—all of which improve only when normal gut flora are introduced.2 Exogenous probiotics are given therapeutically in situations where this naturally beneficial symbiosis has been disturbed, in an attempt to restore normal flora, as in the above animal model. A 2004 Cochrane review reported probiotic therapy to be effective in reducing diarrhoea,3 and a recent report summarising 185 studies found that probiotics successfully treated 68 different conditions in widely diverse populations.4 Sources and selection criteria This review is based on the conclusions of recent randomised clinical trials, Cochrane controlled trials, and European Society of Paediatric Gastroenterology, Hepatitis, and Nutrition reviews of probiotic therapy. We also searched Medline using the keywords “probiotics”, “Lactobacillus”, “Bifidobacterium”, “sepsis”, and “bacteremia”. We reviewed prospective randomised trials of probiotic therapy, looking for reports of intercurrent sepsis, as well as case reports of potentially probiotic associated infections not related to ongoing studies and retrospective population based reviews. We gave preference to articles published after 1995.

1 April 2012 in Seminars in Perinatology
Verified
Journal Article
Closed access
CHCathy Hammerman
Cathy Hammerman
ABAlona Bin-Nun
Alona Bin-Nun
MKMichael Kaplan
Michael Kaplan

1 September 1998 in Clinics in Perinatology
Verified
Journal Article
Closed access
CHCathy Hammerman
Cathy Hammerman
MKMichael Kaplan
Michael Kaplan

1 September 2002 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
CHC. Hammerman
C. Hammerman
DGD. Goldschmidt
D. Goldschmidt
MCM. S. Caplan
M. S. Caplan
MKM. Kaplan
M. Kaplan
RBR. Bromiker
R. Bromiker
AHA. Hochman
A. Hochman

1 December 1998 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
CHCathy Hammerman
Cathy Hammerman
RGRobert Goldstein
Robert Goldstein
MKMichael Kaplan
Michael Kaplan
MEMaya Eran
Maya Eran
DGDoris Goldschmidt
Doris Goldschmidt
LGLawrence M Gartner
Lawrence M Gartner
Potentially toxic oxygen free radicals (OFRs) are generated continuously in neonates. Under physiological conditions, the human body has developed a complex network of antioxidant defenses sufficient to protect cells against oxidative damage. Oxidative stress results from a loss of this protective balance either because of overproduction of free radicals or because of inadequate antioxidant defenses. In prematures, the concentrations of most antioxidant enzymes are reduced, particularly during the early neonatal period ( 1). Impaired antioxidant defenses, occurring at a time when OFR production is both frequent and severe, render the premature neonate extremely susceptible to the development of OFR-mediated diseases.